{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-011212","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.062996+00:00","generated_at":"2026-06-04T01:39:12.386855+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CervoMed posts 2023 net loss of $2.2M; secures $50M private placement; Phase 2b DLB trial on track","bullets":["Net loss $2.2M for 2023; cash $7.8M as of Dec 31, 2023; R&D spending increased to $8.4M.","Private placement of $50M upfront (up to $149.4M with warrants) led by RA Capital; expected to fund through end of 2025.","RewinD-LB Phase 2b enrollment on track to complete Q2 2024; topline data expected Q4 2024.","Appointed Joshua Boger, founder of Vertex Pharmaceuticals, as non-executive Chair of the Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-011212","json":"https://secwatch.observer/filing/0001437749-24-011212.json","markdown":"https://secwatch.observer/filing/0001437749-24-011212.md","text":"https://secwatch.observer/filing/0001437749-24-011212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924011212/0001437749-24-011212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924011212/crvo20240405_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:39:12.386855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dd3f25f43733f55d6cf17baa1cd10da8d51398e4","claim":"CervoMed Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2023. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924011212/0001437749-24-011212-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}